Showing results (11-20 of 95) with videos related to

Sort By:
Pageof 10
Cancers|November 13, 2013
Epigenetic modulating agents as a new therapeutic approach in multiple myelomaKen Maes, Eline Menu, Els Van Valckenborgh, et al.
Oncotarget|November 23, 2017
The therapeutic potential of cell cycle targeting in multiple myelomaAnke Maes, Eline Menu, Kim De Veirman, et al.
Advances in Hematology|October 29, 2010
The effects of forodesine in murine and human multiple myeloma cellsLiesbeth Bieghs, Jo Caers, Elke De Bruyne, et al.
Experimental Hematology & Oncology|July 10, 2024
Fueling CARs: metabolic strategies to enhance CAR T-cell therapyArne Van der Vreken, Karin Vanderkerken, Elke De Bruyne, et al.
Frontiers in Genetics|September 3, 2019
The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple MyelomaPhilip Vlummens, Kim De Veirman, Eline Menu, et al.
Biochemical and Biophysical Research Communications|November 1, 2012
Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myelomaDehui Xu, Jinsong Hu, Elke De Bruyne, et al.
Frontiers in Oncology|January 9, 2019
The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug ResponseEva De Smedt, Hui Lui, Ken Maes, et al.
Brain, Behavior, and Immunity|December 24, 2025
Neural control of Immunotherapy: how Tumor-innervation shapes Anti-Tumor immune responsesHatice Satilmis, Adrien Denis, Karin Vanderkerken, et al.
Frontiers in Oncology|September 5, 2022
Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?Catharina Muylaert, Lien Ann Van Hemelrijck, Anke Maes, et al.
Scientific Reports|October 11, 2018
The genetic landscape of 5T models for multiple myelomaKen Maes, Bram Boeckx, Philip Vlummens, et al.
Pageof 10